Stephana Carelli is group leader at the Pediatric Research Center “Romeo ed Enrica Invernizzi” Foundation, Milano, Italy, and an aggregate professor of pharmacology at the Faculty of Medicine, University of Milan. She holds an M.Sc. in biological sciences and a PhD in physiopathology and pharmacology of metabolic diseases. She has coauthored over 50 publications and holds one patent in this field. Her current research interests include: (1) the role of lncRNAs in epigenetic mechanisms and functions in neurodegeneration/regeneration (Parkinson's disease, ALS) and in the programming and re-programming of stem cells' fate; (2) regenerative medicine for curing neurodegenerative diseases such as spinal cord injury and Parkinson's disease, focusing on both cell therapies based on the application of adult stem cells and on the neuroprotective action of erythropoietin; (3) the application of advanced cell manipulation technologies in regenerative medicine.
Research Keywords & Expertise
mesenchymal stem cells
Organoids
Neural Stem Cells
Cell therapies for neu...
Molecular mechanisms o...
3D culture systems
Cell therapies for neu...
Molecular mechanisms o...
Mechanotransduction an...
LncRNAs in stemness an...
Fingerprints
10%
mesenchymal stem cells
10%
Neural Stem Cells
7%
Cell therapies for neuroegenerative disease (spianl cord injury, Parkinson’s disease)
7%
Cell therapies for neurodegenerative disease (Spinal cord injury, Parkinson’s disease)
5%
Organoids
Short Biography
Stephana Carelli is group leader at the Pediatric Research Center “Romeo ed Enrica Invernizzi” Foundation, Milano, Italy, and an aggregate professor of pharmacology at the Faculty of Medicine, University of Milan. She holds an M.Sc. in biological sciences and a PhD in physiopathology and pharmacology of metabolic diseases. She has coauthored over 50 publications and holds one patent in this field. Her current research interests include: (1) the role of lncRNAs in epigenetic mechanisms and functions in neurodegeneration/regeneration (Parkinson's disease, ALS) and in the programming and re-programming of stem cells' fate; (2) regenerative medicine for curing neurodegenerative diseases such as spinal cord injury and Parkinson's disease, focusing on both cell therapies based on the application of adult stem cells and on the neuroprotective action of erythropoietin; (3) the application of advanced cell manipulation technologies in regenerative medicine.